Alvotech (NASDAQ:ALVO) Sees Large Volume Increase – What’s Next?

Alvotech (NASDAQ:ALVO) saw strong trading volume on Monday . 731,636 shares traded hands during mid-day trading, an increase of 43% from the previous session’s volume of 511,028 shares.The stock last traded at $4.0380 and had previously closed at $3.54.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Wall Street Zen lowered Alvotech from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Barclays cut their price objective on Alvotech from $5.00 to $4.00 and set an “underweight” rating for the company in a research note on Tuesday, March 24th. Zacks Research upgraded Alvotech from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 19th. Weiss Ratings upgraded Alvotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Finally, UBS Group cut their price objective on Alvotech from $10.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.60.

Alvotech Trading Up 16.2%

The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -16.42 and a beta of 0.21. The company has a fifty day moving average price of $3.44 and a two-hundred day moving average price of $4.27.

Alvotech (NASDAQ:ALVO) last issued its earnings results on Tuesday, March 31st. The company reported ($0.09) earnings per share for the quarter. Alvotech had a negative return on equity of 11.92% and a negative net margin of 14.36%.The company had revenue of $105.90 million for the quarter. As a group, equities research analysts expect that Alvotech will post 0.02 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Alvotech by 2.7% in the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock valued at $35,481,000 after acquiring an additional 114,255 shares during the last quarter. Millennium Management LLC lifted its holdings in Alvotech by 1,707.7% in the fourth quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock valued at $1,832,000 after acquiring an additional 337,417 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Alvotech by 88.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after acquiring an additional 122,089 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Alvotech by 10.7% in the fourth quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock valued at $1,308,000 after acquiring an additional 24,667 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in Alvotech in the second quarter valued at approximately $1,782,000.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).